NQO1 and head and neck cancer: β-lapachone is bioactivated by NAD(P)H:quinone oxidoreductase-1 (NQO1), causing futile oxidoreduction that generates high levels of superoxide, and is currently under clinical investigation, as a monotherapy or in combination with gemcitabine, in patients with pancreatic and head-and-neck cancer.